Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years: a plain language summary

This plain language summary from Future Oncology describes long-term results from the RESONATE-2 study in which participants were treated with ibrutinib or with chlorambucil, and then followed for up to 8 years.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia’ and was published in Blood Advances. Read the original article here.